PSTX News and Press, Poseida Therapeutics Inc. From 10/01/21

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting PR Newswire SAN DIEGO , Oct. 1, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic eng...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...

As September started, the healthcare stocks in the S&P 500 returned to post gains after a brief decline last week. Thanks mainly to health insurers, the S&P 500 Healthcare Sector Index posted the biggest one-day gain in more than two weeks on Thursday. Becoming the second-best pe...

Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen Therapeutics (NASDAQ:QLGN) +18%. Azu...

Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, ...

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit Encouraging data confirming activity in a solid tumor indication presented on first nine patients at low dose cohorts in ongoing autologous CAR-T trial in metastat...

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma PR Newswire SAN DIEGO , Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq:...

Poseida Therapeutics (NASDAQ:PSTX): Q2 GAAP EPS of -$0.74 misses by $0.11. As of June 30, 2021, cash, cash equivalents and short-term investments were $237.3 million. Press Release For further details see: Poseida Therapeutics EPS misses by $0.11

Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 PR Newswire SAN DIEGO , Aug. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietar...

Poseida Therapeutics (PSTX) announces the appointment of biotechnology industry veteran Cynthia Collins to the company's board of directors.Collins most recently served as the CEO of Editas Medicine, and prior to that served as the CEO of Human Longevity. For further details ...